Scientific Publications

October 25, 2024
Briquilimab is Well-Tolerated and Effectively Depletes Tissue Resident Mast Cells in Non-Human Primates
October 25, 2024
Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling, and Mast Cell (MC) Degranulation and Survival
October 25, 2024
Briquilimab Potently Blocks Stem Cell Factor (SCF)/c-Kit Signaling in Primary Human Mast Cells
June 14, 2024
Briquilimab Potently Inhibits SCF/c – Kit Signaling, Which Does Not Induce Healthy HSC Apoptosis, But Skews HSC Differentiation Potential
June 2, 2024
Briquilimab, an Anti-Human CD117 Antibody, Effectively Treats Epicutaneous Allergen- Induced Atopic Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117
June 2, 2024
Phase 1b/2a SPOTLIGHT Study in Chronic Inducible Urticaria, Trial-in-Progress
June 1, 2024
Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Briquilimab After Single Subcutaneous (SC) Administration to Healthy Male and Female Participants
June 1, 2024
Briquilimab, an Anti-Human CD117 Antibody, Effectively Treats Cockroach Allergen-Induced Asthma Model in Mice Expressing Chimeric Human/Mouse CD117
June 1, 2024
Phase 1b/2a BEACON Study in Chronic Spontaneous Urticaria, Trial-in-Progress
May 30, 2024
Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling, Mast Cell (MC) Activation and Survival
February 23, 2024
Amelioration Of Mrgprb2-Mediated Anaphylactoid Drug Reactions With Briquilimab, An Anti-CD117 Antibody, Through Mast Cell Depletion In Mice Expressing Chimeric Human And Mouse CD117
February 23, 2024
Briquilimab, an Anti-CD117 Antibody, Prevents Cockroach Allergen Induced Allergic Asthma in Mice Expressing Chimeric Human and Mouse CD117
February 23, 2024
Briquilimab, An Anti-CD117 Antibody, Prevents Passive Systemic Anaphylaxis in Mice Expressing Chimeric Human and Mouse CD117 Through Mast Cell Depletion
December 10, 2023
Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (AHCT)
November 15, 2023
Briquilimab, an anti-CD117 antibody, prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse CD117
February 17, 2023
Subanalysis from Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Cell Transplantation
Subanalysis from Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myleoid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Cell Transplantation
February 17, 2023
Evaluation of Clinical Outcomes and Healthcare Resource Use of Outpatient Allogeneic Stem Cell Transplant in Older Adults with AML/MDS, Using JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning – a Single Center Analysis
Evaluation of Clinical Outcomes and Healthcare Resource Use of Outpatient Allogeneic Stem Cell Transplant in Older Adults with AML/MDS, Using JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning – a Single Center Analysis
February 16, 2023
351 Immune Biomarkers Associated with Chronic Gvhd in Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning in Older Adults with MDS/AML Undergoing Allogeneic HCT
Immune Biomarkers Associated with Chronic Gvhd in Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning in Older Adults with MDS/AML Undergoing Allogeneic HCT
April 26, 2022
LBA4 – Preliminary Data from a Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning Is Well-Tolerated, Facilitates Chimerism and Clearance of Minimal Residual Disease in Older Adults with MDS/AML Undergoing Allogeneic HCT – TCT 2022
TCT2022 AML MDS Presentation
April 1, 2022
Single-Agent Conditioning with Anti-CD117 Antibody JSP191 Shows Donor Engraftment, Naive Lymphocyte Production, and Clinical Benefit in Patients with Severe Combined Immunodeficiency (SCID) – CIS Meeting 2022
December 12, 2021
554 JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID) – ASH 2021
August 27, 2021
5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice
June 4, 2021
Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation
2021 ASCO Annual Meeting Poster
February 8, 2021
LBA5 – Phase 1 Study of JSP191, an Anti-CD117 Monoclonal Antibody, with Low Dose Irradiation and Fludarabine in Older Adults with MRD-Positive AML/MDS Undergoing Allogeneic HCT
TCT2021 MDS AML Submitted Poster
February 8, 2021
249 – Non-Toxic Single Agent Transplant Conditioning with JSP191 (an Anti-CD117 monoclonal antibody) in Infants with Newly Diagnosed Severe Combined Immune Deficiency
TCT2021 SCID Submitted Poster
February 8, 2021
18 – Anti-CD117 Antibody Synergizes with 5-Azacytidine to Augment Engraftment of Hematopoietic Stem Cells in Mice with Sickle Cell Disease
November 5, 2020
5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice
November 5, 2020
First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency
November 13, 2019
Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency
July 31, 2019
Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy
May 9, 2019
Selective CD117+ HSC exchange therapy
May 9, 2019
Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice

Jasper c-Kit Mouse™ Model

The Jasper c-Kit Mouse™ model is proprietary animal model developed by Jasper scientists to enable direct testing of KIT inhibitors across numerous diseases, overcoming the limitations of standard models which do not bind antibodies directed at the human KIT receptor. Jasper believes that the c-Kit Mouse™ model allows for preclinical research with superior translatability to humans and provides a strategic advantage as the Company continue to expand development of briquilimab into additional indications.

Research

If you are interested in becoming a collaborator or sponsor investigator, please submit your proposal to researchproposals@jaspertx.com.

Top